AI药物研发初创公司Pathos AI完成2.37亿美元融资

UPDATED 16:02 EDT / OCTOBER 23 2026 AI AI drug development startup Pathos AI closes $237M investment by Maria Deutscher Pathos AI Inc. today announced that it has raised $237 million in funding at a $3 billion valuation. Pharmaceutical giant Bristol Myers Squibb Co. led the Series E round with participation from several unnamed returning backers. Pathos’ investor roster includes big names such as AstraZeneca plc, NEA and General Atlantic. Pathos is developing cancer drugs using an artificial intelligence platform called Foundry. According to the company, the software has access to about 200 petabytes of oncological data. It also ingests the information generated by Pathos’ drug development programs. Foundry analyzes those datasets to help the company’s researchers pursue their work more efficiently. Pharmaceutical research programs sometimes produce hundreds of drug candidates, molecules that can potentially be turned into medicines. Foundry uses AI agents to pinpoint the most promising molecules. From there, it identifies the patients who could benefit the most from each therapy. Pathos also uses Foundry to plan clinical trials for the drugs that it develops. The company says that its trials are “biomarker-driven.” Biomarkers are biological phenomena that can provide insight into the effectiveness of a drug. They take a wide variety of forms ranging from proteins to patient metrics such as blood pressure. “We are building a platform to systematically improve the probability of success in drug development,” said Pathos Chief Executive Officer Iker Huerga. “Foundry has fundamentally accelerated our ability to identify highly promising clinical assets and integrate them into our pipeline.” Pathos will use its Series E round to finance its drug development efforts. The company stated that its “key priority” is its JSKN016 program, which aims to develop a cancer therapy based on a so-called antibody-drug conjugate. Antibodies are molecules that identify disease-causing cells and bind to them. Once an antibody is attached to a cell, it functions as a kind beacon that draws the attention of the immune system. Immune cells subsequently find the antibody and destroy the cell to which it’s attached. Antibody-drug conjugates use a variation of that approach to treat cancer. They’re effectively upgraded antibodies that contain an antigen, a molecule with therapeutic properties. Antibody-drug conjugates attach to cancer cells and cause them to absorb the antigen, which neutralizes them. Pathos will also use the capital to finance three other drug programs. One of those initiatives is a collaboration with AstraZeneca, which invested in the company last year. The joint program seeks to develop a so-called ER PROTAC drug, which harnesses cells’ built-in material recycling mechanism to treat cancer. The investment from Bristol Myers Squibb that Pathos announced today is part of a broader partnership between the companies. The collaboration also involves Tempus AI Inc., a publicly traded medical data provider . Pathos will pay Tempus $55 million over five years to license anonymized data collected from patients with neurological conditions. The former company will analyze that information using Foundry to gain a better understanding of disease biology. Additionally, it will make both Foundry and the dataset available to Bristol Myers Squibb. The drugmaker will use them to improve its clinical trials and identify patients most likely to benefit from new drugs. Image: Unsplash A message from John Furrier, co-founder of SiliconANGLE: Support our mission to keep content open and free by engaging with theCUBE community. Join theCUBE’s Alumni Trust Network, where technology leaders connect, share intelligence and create opportunities. 15M+ viewers of theCUBE videos, powering conversations across AI, cloud, cybersecurity and more 11.4k+ theCUBE alumni — Connect with more than 11,400 tech and business leaders shaping the future through a unique trusted-based network Are you an AWS customer?  Support SiliconANGLE financially by buying your AWS services from our Marketplace portal page and links: https://siliconangle.com/aws-marketplace/ About SiliconANGLE Media SiliconANGLE Media is a recognized leader in digital media innovation, uniting breakthrough technology, strategic insights and real-time audience engagement. As the parent company of SiliconANGLE, theCUBE Network, theCUBE Research, CUBE365, theCUBE AI and theCUBE SuperStudios — with flagship locations in Silicon Valley and the New York Stock Exchange — SiliconANGLE Media operates at the intersection of media, technology and AI. Founded by tech visionaries John Furrier and Dave Vellante, SiliconANGLE Media has built a dynamic ecosystem of industry-leading digital media brands that reach 15+ million elite tech professionals. Our new proprietary theCUBE AI Video Cloud is breaking ground in audience interaction, leveraging theCUBEai.com neural network to help technology companies make data-driven decisions and stay at the forefront of industry conversations. LATEST STORIES Hybrid infrastructure decisions put AI costs and control in focus What to expect during Intuit Connect: Join theCUBE Oct. 28 What to expect during Oracle AI World: Join theCUBE Oct. 28 Micron’s memory boom: Is the industry's cyclicality really ending? Managed services support keeps neocloud GPU capacity healthy In AI, it's a tale of two diverging investor classes LATEST STORIES Hybrid infrastructure decisions put AI costs and control in focus AI - BY JONATHAN ANTHONY . 3 MINUTES AGO What to expect during Intuit Connect: Join theCUBE Oct. 28 AI - BY DEVONY HOF . 32 MINUTES AGO What to expect during Oracle AI World: Join theCUBE Oct. 28 AI - BY MARK ALBERTSON . 1 HOUR AGO Micron’s memory boom: Is the industry's cyclicality really ending? INFRA - BY DAVE VELLANTE . 3 HOURS AGO Managed services support keeps neocloud GPU capacity healthy INFRA - BY JONATHAN ANTHONY . 4 HOURS AGO In AI, it's a tale of two diverging investor classes AI - BY ROBERT HOF . 6 HOURS AGO